NASDAQ · NTRB
Healthcare · Biotechnology
$3.30
Up+$0.11 (+3.45%)
Updated Aug 16, 2026, 6:54 AM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
NTRB closed at $3.30 after 20 trading sessions, up 7.14% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $3.15 | $3.30 | $3.15 | $3.30 | 4.16K |
| Aug 13, 2026 | $3.13 | $3.26 | $3.09 | $3.19 | 2.35K |
| Aug 12, 2026 | $3.09 | $3.155 | $3.075 | $3.075 | 1.78K |
| Aug 11, 2026 | $3.14 | $3.2561 | $3.14 | $3.18 | 8.03K |
| Aug 10, 2026 | $3.05 | $3.15 | $3.05 | $3.14 | 4.47K |
| Aug 7, 2026 | $2.91 | $3.11 | $2.91 | $3.11 | 6.45K |
| Aug 6, 2026 | $2.90 | $2.915 | $2.90 | $2.915 | 2.99K |
| Aug 5, 2026 | $2.89 | $2.8999 | $2.80 | $2.88 | 14.08K |
| Aug 4, 2026 | $2.84 | $2.9202 | $2.80 | $2.85 | 6.99K |
| Aug 3, 2026 | $2.81 | $2.88 | $2.81 | $2.81 | 5.6K |
| Jul 31, 2026 | $2.93 | $2.9674 | $2.81 | $2.85 | 8.87K |
| Jul 30, 2026 | $3.00 | $3.00 | $2.90 | $2.91 | 4.1K |
| Jul 29, 2026 | $3.00 | $3.00 | $2.88 | $2.88 | 4.81K |
| Jul 28, 2026 | $3.02 | $3.02 | $2.955 | $2.955 | 1.85K |
| Jul 27, 2026 | $3.00 | $3.00 | $2.91 | $2.98 | 7.69K |
| Jul 24, 2026 | $2.9747 | $3.11 | $2.93 | $2.98 | 21.83K |
| Jul 23, 2026 | $3.00 | $3.0799 | $2.92 | $2.93 | 13.73K |
| Jul 22, 2026 | $3.00 | $3.10 | $3.00 | $3.05 | 7.03K |
| Jul 21, 2026 | $3.05 | $3.08 | $3.00 | $3.08 | 4.87K |
| Jul 20, 2026 | $3.09 | $3.1599 | $3.0001 | $3.08 | 3.95K |
The latest Smart Investors Daily articles mentioning NTRB.
NTRB research
Company profile and research snapshot.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jan 22, 2025 | Noble Capital Markets | Outperform | — |
| Jul 26, 2022 | Small Cap Consumer Research | Buy | — |
No generated briefing is available yet.
Benzinga · Jun 11, 2026
Nutriband (NASDAQ:NTRB) reported quarterly losses of $(0.10) per share. This is a 16.67 percent increase over losses of $(0.12) per share from the same period last year. The company reported $433.399 thousand in sales
Benzinga · Feb 17, 2026
Nutriband Inc. today announced that it has signed an exclusive distribution agreement with Costa Rica Based Innomedica for AVERSA Fentanyl upon approval and all sports tape products manufactured at its Pocono
Benzinga · Feb 17, 2026
Yahoo · Jan 30, 2026
ORLANDO, Fla., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) has provided an update to shareholders on the key milestones and discussions from this years Annual Shareholders Meeting, held on Jan 24, 2026 in Orlando, Florida. Details and highlights may be found below. Addition of Two New Directors Allesandro PudduAlessandro Puddu is an Italian Chartered Accountant and Statutory Auditor with over 10 years of experience in audit, corporate advisory and financial re
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NTRB.
